Platelets, diabetes and myocardial ischemia/reperfusion injury

Cardiovascular Diabetology

Volumn 16, Issue 1, 2017, Pages

  Russo, Isabella ^a   Penna, Claudia ^a   Musso, Tiziana ^a   Popara, Jasmin ^a   Alloatti, Giuseppe ^a   Cavalot, Franco ^b   Pagliaro, Pasquale ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antiplatelet therapy; Aspirin; Cardioprotection; Type 2 diabetes

Indexed keywords

ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PRASUGREL; PROSTAGLANDIN H2; TICAGRELOR; TICLOPIDINE; ACETYLSALICYLIC ACID; MICRORNA;

ACETYLATION; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CELL PROTECTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEART PROTECTION; HUMAN; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PLEIOTROPY; PRIMARY PREVENTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; ANIMAL; BLOOD; CARDIAC MUSCLE; COMPLICATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HEART INFARCTION PREVENTION; METABOLISM; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ASPIRIN; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICRORNAS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85020045925     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0550-6     Document Type: Review

References (115)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434-44.
2. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SRK, Forouhi NG, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: reykjavik prospective study and systematic review. PLoS Med. 2010;7:1-12.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34. doi: 10.1056/NEJM199807233390404.
4. Mudaliar S. Intense management of diabetes mellitus: role of glucose control and antiplatelet agents. J Clin Pharmacol. 2004;44:414-22.
5. American Diabetes Association. Executive summary: standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S4-10. doi: 10.2337/dc13-S004.
6. Schrúor K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis aspirin causes a bleeding tendency that involves inhibition of platelet function and prostaglandin biosynthesis. 1997;23.
7. Patrono C, Rocca B. Drug Insight: aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med. 2007;4(1):42-50.
8. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108:542-7. doi: 10.1161/01.CIR.0000081770.51929.5A.
9. Mcadam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 (prostaglandinsplateletsmonocytesibuprofencelecoxib). Pharmacology. 1999;96:272-7.
10. Homorodi N, Kovacs EG, Lee S, Katona E, Shemirani AH, Haramura G, et al. The lack of aspirin resistance in patients with coronary artery disease. J Trans Med. 2016;14:74.
11. Russo I, Viretto M, Barale C, Mattiello L, Doronzo G, Pagliarino A, et al. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes. 2012;61:2913-21.
12. Close SL. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam Clin Pharmacol. 2012;26:19-26.
13. Marcucci R, Grifoni E, Giusti B. On-treatment platelet reactivity: state of the art and perspectives. Vasc Pharmacol. 2016;77:8-18.
14. Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011;72:619-33.
15. Collaboration AT. Collaborative overview of randomised trials of antiplatelet. BMJ. 1994;308:235-46.
16. Antithrombotic Trialists' Collaboration, Trialists A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
17. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA. 2008;300:2134-41.
18. Hebert PR, Schneider WR, Hennekens CH. Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment. J Gen Intern Med. 2009;24:1248-50. doi: 10.1007/s11606-009-1095-5.
19. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
20. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606-17.
21. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-5.
22. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-5.
23. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-5.
24. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010. doi: 10.1016/j.jacc.2010.04.047.
25. Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110-6.
26. Małek LA, Witkowski A. Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. Interv Cardiol. 2010;2:705-18.
27. Cubero Gomez JM, Acosta Martinez J, Mendias Benitez C, Diaz De La Llera LS, Fernandez-Quero M, Guisado Rasco A, et al. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel. Acta Cardiol. 2015;70:728-34.
28. Zaccardi F, Pitocco D, Willeit P, Laukkanen JA. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials. Atherosclerosis. 2015;240:439-45.
29. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College. Diabetes Care. 2010;33:1395-402. doi: 10.1016/j.jvn.2010.10.002.
30. Tamminen MK, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Insulin therapy improves insulin actions on glucose metabolism and aortic wave reflection in type 2 diabetic patients. Eur J Clin Invest. 2003;33:855-60.
31. Neergaard-Petersen S, Hvas A-M, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. Semin Thromb Hemost. 2016;42:234-41.
32. Drzewoski J, Watala C. Is aspirin resistance a real problem in people with type 2 diabetes? Diabetes Care. 2004;27:1245-6.
33. Colwell JA, Cimminiello C. Is aspirin effective in diabetic patients? Yes. J Thromb Haemost. 2005;3:2612-4. doi: 10.1111/j.1538-7836.2005.01720.x.
34. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007;28:1925-7. doi: 10.1093/eurheartj/ehm248.
35. Sacco RL, Sivenius J, Diener H-C. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol. 2005;62:403-8.
36. Angiolillo DJ, Bernardo E, Ramírez C, Costa MA, Sabaté M, Jimenez-Quevedo P, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48:298-304.
37. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin e in type 2 diabetic patients. Diabetes Care. 2003;26:3264-72.
38. Roncaglioni MC, de Gaetano G. Collaborative group of the primary prevention project. low-dose aspirin and vitamin e in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89-95.
39. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
40. Nicolucci A, Standl E. Antiplatelet therapy for every diabetic person? Diabetes Care. 2011;34(Suppl 2):S150-4.
41. Shlomai G, Haran-Appel T, Sella T, Grossman Y, Hauschner H, Rosenberg N, et al. High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study. Cardiovasc Diabetol. 2015;14:80.
42. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42:99-103.
43. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006;97:567-70.
44. Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med. 2014;127:95.
45. Fitzgerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther. 2011;130:213-25.
46. Zhang D, Zhang X, Liu D, Liu T, Cai W, Yan C, et al. Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:50.
47. Feng X, Tucker KL, Parnell LD, Shen J, Lee YC, Ordovás JM, et al. Insulin receptor substrate 1 (IRS1) variants confer risk of diabetes in the Boston Puerto Rican Health Study. Asia Pac J Clin Nutr. 2013;22:150-9.
48. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32:531-40.
49. Schuette C, Steffens D, Witkowski M, Stellbaum C, Bobbert P, Schultheiss H-P, et al. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovasc. Diabetol. 2015;14:15.
50. o317, Sept. 2012. 2012. p. 4-7.
51. Hausenloy D, Yellon D. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123:92-100.
52. Pagliaro P, Penna C. Redox signalling and cardioprotection: translatability and mechanism. Br J Pharmacol. 2015;172:1974-95.
53. Hausenloy DJ, Barrabes JA, Botker HE, Davidson SM, Di Lisa F, Downey J, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016;111:70.
54. Kleinbongard P, Skyschally A, Heusch G. Cardioprotection by remote ischemic conditioning and its signal transduction. Pflugers Arch. 2017;469:159-81.
55. Penna C, Granata R, Tocchetti CG, Gallo MP, Alloatti G, Pagliaro P. Endogenous cardioprotective agents: role in pre and postconditioning. Curr Drug Targets. 2015;16:843-67.
56. Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015;172:1913-32.
57. Penna C, Perrelli M-G, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal. 2013;18:556.
58. Heusch G, Rassaf T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning??? Circ Res. 2016;119:676-95.
59. Bell RM, Bøtker HE, Carr RD, Davidson SM, Downey JM, Dutka DP, Heusch G, Ibanez B, Macallister R, Stoppe C, Ovize M, Redington A, Walker JM, Yellon DM. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol. 2016;111(4):41. doi: 10.1007/s00395-016-0558-1.
60. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014. doi: 10.1124/pr.113.008300.
61. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. 2011;14:781-90.
62. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54:2360-4.
63. Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ. The diabetic heart: too sweet for its own good? Cardiol Res Pract. 2012;2012:845698.
64. Whittington HJ, Harding I, Stephenson CIM, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res. 2013;99:694-704.
65. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007;56:127-36.
66. Wang B, Raedschelders K, Shravah J, Hui Y, Safaei HG, Chen DDY, et al. Differences in myocardial PTEN expression and Akt signalling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery. Clin Endocrinol. 2011;74:705-13.
67. Lejay A, Fang F, John R, Van JAD, Barr M, Thaveau F, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 2016;91:11-22. doi: 10.1016/j.yjmcc.2015.12.020.
68. del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res. 2002;55:642-59.
69. Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, et al. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol. 2001;280:H1744-50.
70. Hassouna A, Loubani M, Matata BM, Fowler A, Standen NB, Galinanes M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res. 2006;69:450-8.
71. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418-58.
72. Kereiakes DJ. Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. Rev Cardiovasc Med. 2009;10:72-82.
73. Bangalore S, Toklu B, Kotwal A, Volodarskiy A, Sharma S, Kirtane AJ, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 2014;349:g6419.
74. Yang X-M, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013. doi: 10.1007/s10557-012-6436-7.
75. Yang X-M, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. Platelet P2Y blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18:251-62.
76. Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J. Cardiovasc Pharmacol Ther. 2014;19:179-90.
77. Yang XM, Cui L, White J, Kuck J, Ruchko MV, Wilson GL, Alexeyev M, Gillespie MN, Downey JM, Cohen MV. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Res Cardiol. 2015;110(2):3. doi: 10.1007/s00395-014-0459-0.
78. Cohen MV, Yang XM, White J, Yellon DM, Bell RM, Downey JM. Cangrelor-mediated cardioprotection requires platelets and sphingosine phosphorylation. Cardiovasc Drugs Ther. 2016;30:229-32.
79. Bell RM, Sivaraman V, Kunuthur SP, Cohen MV, Downey JM, Yellon DM. Cardioprotective properties of the platelet p2y12 receptor inhibitor, cangrelor: protective in diabetics and reliant upon the presence of blood. Cardiovasc Drugs Ther. 2015;29:415-8.
80. Yang BC, Virmani R, Nichols WW, Mehta JL. Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts. Circ Res. 1993;72:1181-90.
81. Yang B, Mehta P, Mehta JL. Platelet-mediated cardioprotective effect against ischemia-reperfusion injury in isolated rat hearts: role of platelet number and contribution of supernatant of aggregated platelets. J Cardiovasc Pharmacol Ther. 1998;3:23-8. doi: 10.1177/107424849800300103.
82. Russo I, Femminò S, Barale C, Cavalot F, Tullio F, Penna C, et al. Platelets from poorly controlled type 2 diabetes subjects show an impaired ability to protect against the cardiac ischaemia/reperfusion injury. Abstr. 52nd EASD Annu. Meet. Munich: Diabetologia; 2016.
83. Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121-6.
84. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525-7.
85. Santilli F, Lapenna D, La Barba S, Davì G. Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radic Biol Med. 2015;80:101-10.
86. Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109:2524-8.
87. Soma P, Swanepoel AC, du Plooy JN, Mqoco T, Pretorius E. Flow cytometric analysis of platelets type 2 diabetes mellitus reveals "angry" platelets. Cardiovasc Diabetol. 2016;15:52.
88. Soma P, Pretorius E. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:96.
89. Wang W, Lau WB, Wang Y, Ma X, Li R. Reduction of CTRP9, a novel anti-platelet adipokine, contributes to abnormal platelet activity in diabetic animals. Cardiovasc Diabetol. 2016;15:6.
90. Mazzucco L, Medici D, Serra M, Panizza R, Rivara G, Orecchia S, et al. The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. Transfusion. 2004;44:1013-8. doi: 10.1111/j.1537-2995.2004.03366.x.
91. O'Connell SM, Impeduglia T, Hessler K, Wang XJ, Carroll RJ, Dardik H. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen. 2008;16:749-56. doi: 10.1111/j.1524-475X.2008.00426.x.
92. Hibi H, Yamada Y, Kagami H, Ueda M. Distraction osteogenesis assisted by tissue engineering in an irradiated mandible: a case report. Int J Oral Maxillofac Implants. 2006;21:141-7.
93. Kubota S, Kawata K, Yanagita T, Doi H, Kitoh T, Takigawa M. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J Biochem. 2004;136:279-82.
94. Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AM, et al. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials. 2003;24:3095-100.
95. Pieri L, Rinaldi B, Domenici L, Bacci S, Filippelli A, Capuano A, et al. Blood-borne cells involved in arterial repair upon experimental incision injury. Histol Histopathol. 2008;23:19-32.
96. Patel MB, Kilgore KS, Ortolano GA, Gryboski CL, Qureshi MA, Marcovitz P, et al. Conditioned blood reperfusion during angioplasty (CoBRA) treatment of acute myocardial infarction. Perfusion. 2001;16:39-49. doi: 10.1177/026765910101600i106.
97. Aiken JW, Shebuski RJ, Miller OV, Gorman RR. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther. 1981;219:299-308.
98. Yee ES, Price DC, Aherne T, Ebert PA. Intracoronary platelet aggregation: pattern of deposition after ischemia, cardioplegia, and reperfusion. J Surg Res. 1986;40:499-503.
99. Vanhoutte PM, Houston DS. Platelets, endothelium, and vasospasm. Circulation. 1985;72:728-34.
100. Alloatti G, Montrucchio G, Emanuelli G, Camussi G. Platelet-activating factor (PAF) induces platelet/neutrophil co-operation during myocardial reperfusion. J Mol Cell Cardiol. 1992;24:163-71.
101. Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic, reperfused heart. Exp. Biol. Med. 2011. doi: 10.1258/ebm.2011.010316.
102. Penna C, Perrelli M-G, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal. 2012;18:556.
103. Ferland DJ, Watts SW. Chemerin: a comprehensive review elucidating the need for cardiovascular research. Pharmacol Res. 2015;99:351-61.
104. Wittamer V, Franssen J-D, Vulcano M, Mirjolet J-F, Le Poul E, Migeotte I, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-85. doi: 10.1084/jem.20030382.
105. Du XY, Zabel BA, Myles T, Allen SJ, Handel TM, Lee PP, et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem. 2009;284:751-8. doi: 10.1074/jbc.M805000200.
106. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type2 diabetes mellitus with or without ischaemic heart disease. Diabet Med. 2011;28:1194-200. doi: 10.1111/j.1464-5491.2011.03353.x.
107. Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, et al. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab. 2012;58:539-44.
108. Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M. Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis. 2015;235:256-62.
109. Femminò S, Russo I, Cavalot F, Barale C, Tullio F, Penna C, Pagliaro P. Platelets Protect Against Myocardial Injury, but Platelets From Patients With Type 2 Diabetes Mellitus (T2DM) Lose their Protective Properties. Meeting Abstracts Ischemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery, May 12th-13th, 2016, Barcelona. J Mol Cell Cardiol. 2016;97:S1-8 Abstr 31
110. Clancy L, Freedman JE. Blood-derived extracellular rna and platelet pathobiology: adding pieces to a complex circulating puzzle. Circ Res. 2016;118:374-6.
111. Mcmanus DD, Freedman JE. MicroRNAs in platelet function and cardiovascular disease. Nat Rev Cardiol. 2015. doi: 10.1038/nrcardio.2015.101.
112. Lindsay CR, Edelstein LC. MicroRNAs in platelet physiology and function. Semin Thromb Hemost. 2016;42:215-22. doi: 10.1055/s-0035-1570077.
113. Rome S. Are extracellular microRNAs involved in type 2 diabetes and related pathologies? Clin Biochem. 2013;46:937-45.
114. Binderup HG, Houlind K, Madsen JS, Brasen CL. Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. Clin Biochem. 2016;49:1167-72.
115. Kok MGM, Mandolini C, Moerland PD, de Ronde MWJ, Sondermeijer BM, Halliani A, et al. Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity. Int J Cardiol. 2016;203:262-3.